Kezar Life Sciences

Kezar Life Sciences: Clinical stage biotechnology company pioneering first-in-class, small molecule therapies designed to inhibit multiple disease-driving cellular pathways by targeting key intracellular proteins. The Company is advancing two differentiated therapeutic approaches: Selective Immunoproteasome Inhibition, for the treatment of autoimmune diseases through immune modulation versus direct immunosuppression; and Protein Secretion Inhibition, halting the secretion of target proteins that contribute to a range of cancers and autoimmune diseases. Lead candidate, zetomipzomib (KZR-616), a selective immunoproteasome inhibitor, is being evaluated in Phase 2 clinical trials for lupus nephritis and autoimmune hepatitis, and KZR-261, a first-in-class inhibitor of the Sec61 translocon developed using the Company’s novel discovery Protein Secretion Inhibition Platform, is undergoing a Phase 1 clinical trial for the treatment of advanced/metastatic solid tumors.
Based in...
US - Pacific
Clinical Stage
Phase l or ll
Disease Space
Autoimmune, Oncology
Public, USA
Market Cap
500MM - 1B
Therapeutic Modalities
Small Molecule
4000 Shoreline Court
Suite 300
South San Francisco, CA 94080
United States

Company Participants at Solebury 1x1 Management Access Event 2023

  • John Fowler, CEO, Co-Founder
  • Nick Mordwinkin , PhD, Chief Business Officer

Upcoming Company Event Participation

Top 10 Holders of Kezar Life Sciences Inc

Institution OS (%) Position Mkt Val ($MM) Source Filing Date
Avidity Partners Management LP 7.92 5,414,400 40.07 13F 9/30/22
State Street Corp. 5.17 3,537,701 26.18 13F 9/30/22
Suvretta Capital Management LLC 4.79 3,275,520 24.24 13F 9/30/22
Bellevue Asset Management AG 4.43 3,031,000 22.43 13F 9/30/22
Millennium Management LLC 4.33 2,962,268 21.92 13F 9/30/22
The Vanguard Group, Inc. 4.29 2,920,696 21.61 Funds 10/31/22
Vanguard Group, Inc. (Subfiler) 4.27 2,917,519 21.59 13F 9/30/22
BlackRock Fund Advisors 3.59 2,451,195 18.14 13F 9/30/22
Victory Capital Management, Inc. (Investment Management) 3.45 2,359,492 17.46 13F 9/30/22
OrbiMed Advisors LLC 2.59 1,771,700 13.11 13F 9/30/22
Ownership data is sourced through FactSet.

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2022 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.